Business
Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023
Company reaches major strategic inflection point, with operations and revenue ramp-up underwayInaugural 2026 guidance introduced; target to achieve:More than
About this update from Cosmos Health Inc.
[{"type":"text","content":"Company reaches major strategic inflection point, with operations and revenue ramp-up underwayInaugural 2026 guidance introduced; target to achieve:More than $180 million in gross annual revenueEBITDA in excess of $20 millionSo far in 2023, among other achievements:Completed three acquisitionsMade notable progress in R&DNutraceutical brands \"Sky Premium Life\" and \"Mediterranation\" experiencing significant market success, expanding into new sales channels and geographiesMaintains a robust balance sheet with negligible debt and a strong, diversified asset baseActively exploring initiatives to enhance shareholder valueCHICAGO, IL / ACCESSWIRE / September 12, 2023 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today announced its inaugural 2026 revenue and EBITDA guidance and released a recap of the Company's significant activities and events reported so far in 2023.Greg Siokas, Chief Executive Officer of Cosmos Health, stated: \"We are pleased to announce guidance based on our long-term outlook to achieve substantial growth and profitability. By the end of 2026, our goal is to achieve two significant milestones: surpassing $180 million in gross annual revenue and attaining profitability, with EBITDA expected to exceed $20 million. This projection has been carefully formulated, taking into account several factors. Notably, we have a clear view of our existing logistics distribution businesses, which consistently generate stable cash flows. Additionally, revenue is expected to be augmented by bolt-on acquisitions, which would expand our distribution network, leading to growth in accretive cash flows. Furthermore, strategic acquisitions such as Cana will play a pivotal role, enabling us to vertically integrate and enter into contract manufacturing, as well as broaden our production capabilities to medicines. Our high-margin nutraceutical brands are also expected to contribute significantly to this growth. It's important to mention that our projections do not include the potential upside from any future R&D products or various tech projects, including ZipDoctor. We have taken a conserv...